This personalized vaccine can enhance the phagocytosis of autologous tumor antigens by dendritic cells (DCs) and facilitate DCs maturation through TLR4,[14] and build an efficient immune protection to prolong the survival while maintaining good biocompatibility. The gene discussed is TLR4; the disease is neoplasm.